Lantern Pharma Maps Out Multi-Agent AI Platform for Drug Discovery
Lantern Pharma unveiled a product roadmap for withZeta.ai, its AI platform for oncology research and drug development, adding two major capability tracks: ZetaSwarm, a multi-agent reasoning system, and ZetaOmics, a computational biology toolkit. The company also plans enterprise-grade features for institutional deployment.
withZeta.ai is already commercially available with subscription pricing. The new capabilities are expected to launch over the coming year.
How ZetaSwarm Works
ZetaSwarm coordinates multiple specialist AI agents that operate in parallel on different aspects of a research question, then synthesize their findings into a single answer. Each agent has access to specific tools and domain expertise.
The system crosses three research modes-Explorer, Investigator, Reporter-with five domain specialists: medicinal chemistry, clinical trial strategy, clinical oncology, biomarkers, and general scientific reasoning. That creates 15 distinct agent configurations, each with tailored tool access and reasoning depth.
For a query like "Profile this rare CNS indication for biomarker-stratified trial design," a coordinator agent would break it down and dispatch it to specialist subagents. A biomarker expert examines genomic data. A clinical trial strategist evaluates the competitive landscape. A medicinal chemist assesses compound candidates and blood-brain barrier permeability. A clinical oncologist contextualizes treatment setting. A reviewer agent then critically evaluates the synthesis before delivery to the user.
The system runs on withZeta.ai's existing infrastructure, reusing tested tool execution, concurrency handling, and audit logging.
ZetaOmics: Real-Time Computational Biology
ZetaOmics operates as both a standalone bioinformatics toolkit and as a computational layer that ZetaSwarm agents can invoke during analysis. It brings multiomic biomarker and drug response analytics directly into the conversational research environment.
The toolkit is being built against public datasets including TCGA, GTEx, TARGET, NCBI GEO, and NCI-60, with planned integration of genomic alteration data through cBioPortal. Planned capabilities include differential expression analysis, pathway enrichment, genomic alteration queries, drug-response correlation analysis, survival analysis, and cross-cohort expression comparisons.
Future versions will allow researchers to add their own datasets, extending the platform to internal cohorts, proprietary screening data, and customer-specific multiomic libraries.
Enterprise Deployment Features
Lantern is developing enterprise capabilities for pharma companies, academic medical centers, biotech research groups, and cancer centers. These include workspace and organization-level accounts with shared conversation history and role-based access controls.
The company also plans comprehensive audit trails that surface execution logging-who asked what, which tools were invoked, what data was accessed, token usage, and cost-in a queryable, exportable format suitable for regulated environments.
A new feature will allow enterprise customers to bring proprietary datasets and internal publications into withZeta.ai through a private knowledge base. The platform's existing hybrid retrieval engine will be extended with a new ingestion pipeline.
Market Positioning
The AI-focused drug development and discovery tools market is valued at nearly $15 billion. withZeta.ai represents a non-dilutive revenue stream for Lantern shareholders through subscription payments.
Panna Sharma, CEO of Lantern Pharma and founder of withZeta.ai, said the platform addresses a gap in current oncology AI: researchers typically choose between "a brilliant AI generalist that has read everything and understands nothing specific" or "legacy software that has understood a few fixed routines for twenty years and cannot learn anything new." The roadmap positions withZeta.ai as a third option-a multi-agentic platform that knows what it doesn't know and improves with each research session.
Lantern is a clinical-stage precision oncology company advancing a pipeline of small molecule drug candidates and antibody-drug conjugate programs across multiple solid tumor and hematologic malignancies.
Your membership also unlocks:
